101 related articles for article (PubMed ID: 21256872)
1. GLP-1-derived nonapeptide GLP-1(28-36)amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes.
Tomas E; Stanojevic V; Habener JF
Regul Pept; 2011 Apr; 167(2-3):177-84. PubMed ID: 21256872
[TBL] [Abstract][Full Text] [Related]
2. GLP-1 (9-36) amide metabolite suppression of glucose production in isolated mouse hepatocytes.
Tomas E; Stanojevic V; Habener JF
Horm Metab Res; 2010 Aug; 42(9):657-62. PubMed ID: 20645222
[TBL] [Abstract][Full Text] [Related]
3. GLP-1-derived nonapeptide GLP-1(28-36)amide inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice.
Tomas E; Wood JA; Stanojevic V; Habener JF
Regul Pept; 2011 Aug; 169(1-3):43-8. PubMed ID: 21549160
[TBL] [Abstract][Full Text] [Related]
4. GLP-1-derived nonapeptide GLP-1(28-36)amide represses hepatic gluconeogenic gene expression and improves pyruvate tolerance in high-fat diet-fed mice.
Ip W; Shao W; Chiang YT; Jin T
Am J Physiol Endocrinol Metab; 2013 Dec; 305(11):E1348-58. PubMed ID: 24085036
[TBL] [Abstract][Full Text] [Related]
5. In vitro metabolism of the glucagon-like peptide-1 (GLP-1)-derived metabolites GLP-1(9-36)amide and GLP-1(28-36)amide in mouse and human hepatocytes.
Sharma R; McDonald TS; Eng H; Limberakis C; Stevens BD; Patel S; Kalgutkar AS
Drug Metab Dispos; 2013 Dec; 41(12):2148-57. PubMed ID: 24056839
[TBL] [Abstract][Full Text] [Related]
6. Glucagon-like peptide-1(9-36)amide metabolite inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice.
Tomas E; Wood JA; Stanojevic V; Habener JF
Diabetes Obes Metab; 2011 Jan; 13(1):26-33. PubMed ID: 21114600
[TBL] [Abstract][Full Text] [Related]
7. GLP-1(28-36) improves β-cell mass and glucose disposal in streptozotocin-induced diabetic mice and activates cAMP/PKA/β-catenin signaling in β-cells in vitro.
Shao W; Wang Z; Ip W; Chiang YT; Xiong X; Chai T; Xu C; Wang Q; Jin T
Am J Physiol Endocrinol Metab; 2013 Jun; 304(12):E1263-72. PubMed ID: 23571712
[TBL] [Abstract][Full Text] [Related]
8. Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis.
Tomas E; Habener JF
Trends Endocrinol Metab; 2010 Feb; 21(2):59-67. PubMed ID: 20018525
[TBL] [Abstract][Full Text] [Related]
9. Engineered glucagon-like peptide-1-producing hepatocytes lower plasma glucose levels in mice.
Riedel MJ; Lee CW; Kieffer TJ
Am J Physiol Endocrinol Metab; 2009 Apr; 296(4):E936-44. PubMed ID: 19190262
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide-2 receptor modulates islet adaptation to metabolic stress in the ob/ob mouse.
Bahrami J; Longuet C; Baggio LL; Li K; Drucker DJ
Gastroenterology; 2010 Sep; 139(3):857-68. PubMed ID: 20546737
[TBL] [Abstract][Full Text] [Related]
11. GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly?
Taing MW; Rose FJ; Whitehead JP
Drug Des Devel Ther; 2014; 8():677-88. PubMed ID: 24940046
[TBL] [Abstract][Full Text] [Related]
12. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways.
Ban K; Noyan-Ashraf MH; Hoefer J; Bolz SS; Drucker DJ; Husain M
Circulation; 2008 May; 117(18):2340-50. PubMed ID: 18427132
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis.
Lee YS; Shin S; Shigihara T; Hahm E; Liu MJ; Han J; Yoon JW; Jun HS
Diabetes; 2007 Jun; 56(6):1671-9. PubMed ID: 17369525
[TBL] [Abstract][Full Text] [Related]
14. GLP-1 effect upon the GPI/IPG system in adipocytes and hepatocytes from diabetic rats.
Márquez L; González N; Puente J; Valverde L; Villanueva-Peñacarrillo ML
Diabetes Nutr Metab; 2001 Oct; 14(5):239-44. PubMed ID: 11806463
[TBL] [Abstract][Full Text] [Related]
15. GLP-1(32-36)amide Pentapeptide Increases Basal Energy Expenditure and Inhibits Weight Gain in Obese Mice.
Tomas E; Stanojevic V; McManus K; Khatri A; Everill P; Bachovchin WW; Habener JF
Diabetes; 2015 Jul; 64(7):2409-19. PubMed ID: 25858562
[TBL] [Abstract][Full Text] [Related]
16. Effects of glucagon-like peptide 1 on the hepatic glucose metabolism.
D'Alessio D; Vahl T; Prigeon R
Horm Metab Res; 2004; 36(11-12):837-41. PubMed ID: 15655716
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis.
Svegliati-Baroni G; Saccomanno S; Rychlicki C; Agostinelli L; De Minicis S; Candelaresi C; Faraci G; Pacetti D; Vivarelli M; Nicolini D; Garelli P; Casini A; Manco M; Mingrone G; Risaliti A; Frega GN; Benedetti A; Gastaldelli A
Liver Int; 2011 Oct; 31(9):1285-97. PubMed ID: 21745271
[TBL] [Abstract][Full Text] [Related]
18. The major glucagon-like peptide-1 metabolite, GLP-1-(9-36)-amide, does not affect glucose or insulin levels in mice.
Rolin B; Deacon CF; Carr RD; Ahrén B
Eur J Pharmacol; 2004 Jun; 494(2-3):283-8. PubMed ID: 15212985
[TBL] [Abstract][Full Text] [Related]
19. Role of glial cell-line derived neurotropic factor family receptor alpha2 in the actions of the glucagon-like peptides on the murine intestine.
McDonagh SC; Lee J; Izzo A; Brubaker PL
Am J Physiol Gastrointest Liver Physiol; 2007 Aug; 293(2):G461-8. PubMed ID: 17585017
[TBL] [Abstract][Full Text] [Related]
20. An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis.
Baggio LL; Huang Q; Cao X; Drucker DJ
Gastroenterology; 2008 Apr; 134(4):1137-47. PubMed ID: 18313669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
